MarginsXMarginsX
Home › Markets › Health Care › MENS

Jyong Biotech Ltd. (MENS)

MENS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.77
+0.57% on the day
Market cap
$134.6M
Micro cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerMENS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryTaiwan
IPO year2025
SEC CIK0001954488
SEC industry codePharmaceutical Preparations
Incorporated inCayman Islands

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
4.6 months
$1.2M cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
Yes
20-F filed May 15, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"We concluded that there is substantial doubt about our ability to continue as a going concern for a period of one year from the date that the unaudited interim consolidated financial statements included in this registration statement were issued."
20-F 2026-05-15
Cash and burn$1.2M cash; operating cash flow -$760K a quarter.Report 2025-12-31
Shares outstanding76,027,667 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorWWC, P.C., San Mateo, California, United StatesPCAOB Form AP 2026-05-15
Late filings, 12 months1 NT noticeNT 20-F 2026-04-29
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$4.7M-$3.0M$1.2M$17.5MNeeds four quarters20-F 2026-05-15
FY 2024
2024-12-31
Not filed-$3.0M-$3.6M$101KNo debt tagsNeeds four quarters20-F 2026-05-15
FY 2023
2023-12-31
Not filed-$4.4M-$2.6M$1.7MNo debt tagsNeeds four quarters20-F 2026-05-15

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B42025-06-18
Latest annual report
ANNUAL REPORT
20-F2026-05-15
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-02-06

Source: SEC EDGAR submissions feed, 73 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.2%
1 month-13.7%
3 months-14.6%
Year to date-55.4%
1 year-95.4%
From 52-week high-95.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MSLESatellos Bioscience Inc.$6.47-2.34%$137.3M
NTHINeOnc Technologies Holdings Inc.$4.54-7.54%$131.0M
CNTNCanton Strategic Holdings Inc.$1.64-4.09%$130.7M
MGNXMacroGenics Inc.$2.17-1.36%$138.7M
RNAAtrium Therapeutics Inc.$6.43-14.38%$138.7M
SIONSionna Therapeutics Inc.$3.12-6.31%$141.1M
ALXOALX Oncology Holdings Inc.$1.00-3.85%$124.9M
AKBAAkebia Therapeutics Inc.$0.4486-5.40%$124.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier